StockData
TNONNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as TNONW

Tenon Medical, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.45−0.25 (-9.26%)

Close on Oct 19, 2026

Market cap
$804
P/E (TTM)
–
Dividend yield
–

About Tenon Medical

Surgical & Medical Instruments & Apparatus, SIC 3841

Tenon Medical, Inc. is a medical device company that develops surgical solutions for sacro-pelvic disorders, particularly conditions affecting the sacroiliac joint that cause lower back pain. Its primary product offerings include The Catamaran SI Joint Fusion System, which utilizes a single titanium implant through a less invasive approach, and The SImmetry + SI Joint Fusion System, a minimally invasive lateral access system designed to achieve biological fusion across the joint. The company's solutions target clinical procedures including primary sacroiliac joint fusions, revisions of failed implants, and fusions performed adjacent to spine fusion constructs. The company serves healthcare providers, including surgeons, clinicians, and hospitals treating adult sacroiliac joint pathology.

Operations are centered in the United States, which serves as the primary commercial focus for its surgical systems. Tenon Medical maintains its principal executive offices and headquarters in Los Gatos, California, after relocating from San Ramon, California.

Summary of the business section of Tenon Medical's latest annual report, written by StockData.

Company profile

Company

Legal name
Tenon Medical, Inc.
Founded
2012
Headquarters
Los Gatos, CA
Address
104 Cooper Ct. 95032
Phone
(408) 649-5760
Employees
26, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Haskell & White LLP, Irvine, California

Stock & identifiers

Ticker
TNON
Other tickers
TNONW
Exchange
Nasdaq
IPO date
Apr 27, 2022
Shares outstanding
1M, Aug 13, 2026
Public float
$7.32M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-35 reverse, Aug 13, 2026; 1-for-35 reverse, Aug 10, 2026; 1-for-8 reverse, Nov 14, 2024; 1-for-8 reverse, Sep 6, 2024; 1-for-10 reverse, Nov 14, 2023; 1-for-10 reverse, Nov 2, 2023
SEC CIK
1560293
CUSIP
88066N113
ISIN
US88066N1138
EIN
45-5574718

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Steven M. FosterCEO and President, Director262,962
Richard GinnChief Technology Officer, Director167,357
Kevin WilliamsonChief Financial Officer2,580
Wyatt D. GeistChief Innovation Officer644,735
Nathaniel A. GraweyChief Commercial Officer482,865
Stephen HochschulerDirector38,395
Ivan HowardDirector85,112
Kristine M. JacquesDirector20,876
Richard FerrariDirector293,375
Robert K. WeigleDirector18,284

Employees

Headcount reported in annual reports

“of March 27, 2026, we have a total of 26 employees, all of whom are full-time, and nine senior consulting advisors of various specialty”

Corporate history

Events identified from SEC filings